- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT05953207
Traitements non pharmacologiques des parasomnies (Hypnosomnia)
Évaluation de l'efficacité des traitements non pharmacologiques des parasomnies : un essai contrôlé randomisé
The goal of this clinical trial is to compare the efficacy of non-pharmacological treatments (medical hypnosis and standard treatment) in patients with a non-REM parasomnia diagnosis (N=60).
Participants are randomly assigned to one of the two treatments. Treatment consists of 3 sessions. Participants receiving the standard treatment (i.e., sleep hygiene and episode risk reduction) may subsequently receive medical hypnosis.
Participation in the study involves 5 visits in total: 3 treatment visits and 2 study visits to the hospital (CHUV).
- An initial study visit to provide information and collect questionnaires prior to the start of treatment. An initial non-therapeutic hypnosis session will be carried out during electroencephalography (EEG). Estimated duration: 2h.
- A second study visit at the end of treatment, including questionnaires about your sleep and treatment. A shorter non-therapeutic hypnosis session and a second EEG will be performed. Estimated duration: 1h30. This visit may also be followed by an overnight polysomnography, according to patient's choice (if performed, estimated total duration 12 hrs).
This study also involves monitoring patients' sleep for 10 nights before and after treatment: they will fill in a sleep diary and use an infrared camera.
For the validation of the EEG methodology, healthy volunteers (N=50) will complete a unique visit resembling the initial study visit of patients.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
Canton of Vaud
-
Lausanne, Canton of Vaud, Suisse, 1005
- Centre hospitalier universitaire vaudois (CHUV)
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Patients with NREM parasomnia (N=60):
Inclusion Criteria:
- Non-REM parasomnias diagnosis according to the international classification disease of sleep disorders
- Willling and able to give informed consent
- Reporting at least one parasomniac episode per month
- Reporting at least one parasomniac episode the month prior
Exclusion Criteria:
- Refusal to use the home video recording device
- Current or planned intake (during the next 2 months) of medications/substances that may interfere with sleep architecture (e.g., hypnotics, neuroleptics, antidepressants, benzodiazepines)
- A comorbid significant somatic disease altering the brain (e.g., cancer, epilepsy, multiple sclerosis, dementia)
- A comorbid sleep disorder (e.g., apnea-hypopnea index (AHI) >= 20/hour, REM sleep behaviour disorder, restless legs syndrome with symptoms more than 2 days/week)
- A comorbid psychiatric disorder (e.g., severe depressive or anxiety disorder or psychotic disorder)
Healthy volunteers (N=50):
Inclusion Criteria:
- Adult (≥ 18 yo) willing and able to give informed consent.
Exclusion criteria:
- Presence of NREM parasomnias diagnosis, or any other concomitant sleep disorder;
- Current intake of medications/substances that may interfere with sleep architecture (e.g., hypnotics, neuroleptics, antidepressants, benzodiazepines);
- A comorbid significant somatic disease altering the brain (e.g., cancer, epilepsy, multiple sclerosis, dementia);
- A comorbid psychiatric disorder (e.g., severe depressive or anxiety disorder or psychotic disorder);
- Current history of psychiatric or neurological disorders (e.g., migraines).
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation croisée
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Medical hypnosis (HYP) (N=30)
3 medical hypnosis interventions |
Hypnosis intervention with specific suggestions (i.e., patient's own dreamlike mentation) |
|
Comparateur actif: Standard Of Care (SOC) (N=30)
3 standard of care quality and sleep safety interventions |
Sleep hygiene and safety education session |
|
Aucune intervention: Healthy volunteers (N=50)
Unique EEG visit resembling the initial study visit of patients with NREM parasomnias |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change, from pre-treatment, of mean number of parasomniac episodes at 9 weeks
Délai: Over a recording period of 10 consecutives nights, 2 weeks before (pre-treatment) and 3 weeks after (at 9 weeks) the treatment
|
Parasomniac episodes scored on infrared home video recording |
Over a recording period of 10 consecutives nights, 2 weeks before (pre-treatment) and 3 weeks after (at 9 weeks) the treatment
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Duration of parasomniac episodes
Délai: Over a recording period of 10 consecutives nights, 2 weeks before (pre-treatment) and 3 weeks after (at Week 9) treatment
|
Using home video recording |
Over a recording period of 10 consecutives nights, 2 weeks before (pre-treatment) and 3 weeks after (at Week 9) treatment
|
|
Rate of confusional arousals, sleepwalking and sleep terrors episodes
Délai: Over a recording period of 10 consecutives nights, 2 weeks before (pre-treatment) and 3 weeks after (at Week 9) the treatment
|
Categorization of parasomniac episodes' complexity (confusional arousals, sleepwalking, sleep terrors) using home video recording |
Over a recording period of 10 consecutives nights, 2 weeks before (pre-treatment) and 3 weeks after (at Week 9) the treatment
|
|
Incidence of emotions related to parasomniac episodes
Délai: Through study duration, an average of 9 weeks
|
Emotional impact of parasomniac episodes using questionnaires (e.g., What emotions did you feel during these episodes?; Do you have negative emotions related to your parasomnias?) |
Through study duration, an average of 9 weeks
|
|
Quality of life score
Délai: At Day 0, Week 11 and Week 18
|
Using a standardized questionnaire: World Health Organization Quality Of Life-BREF (WHOQOL-BREF). Score ranging from 0 to 100, higher score denoting greater perceived quality of life. |
At Day 0, Week 11 and Week 18
|
|
Anxiety and depression scores
Délai: At Day 0 and Week 11
|
Using a standardized questionnaire: Hospital Anxiety and Depression Scale (HADS). Subscale score ranging from 3 to 21, score >8 denotes anxiety or depression. |
At Day 0 and Week 11
|
|
Traumatic events score
Délai: At Day 0
|
Using a standardized questionnaire: Life Event Checklist for DSM-5 (LEC-5). It does not yield a total score or a composite score. |
At Day 0
|
|
Fatigue score
Délai: At Week 2, Week 11 and Week 18
|
Using a standardized questionnaire: Pichot's fatigue scale. Score ranging from 0 to 32, score >22 denotes excessive fatigue. |
At Week 2, Week 11 and Week 18
|
|
Sleepiness score
Délai: At Week 2, Week 11 and Week 18
|
Using a standardized questionnaire: Epworth Sleepiness Scale (ESS). Score ranging from 0 to 24, higher score denoting higher daytime sleepiness. |
At Week 2, Week 11 and Week 18
|
|
Sleep quality score
Délai: At Week 2, Week 11 and Week 18
|
Using a standardized questionnaire: Pittsburgh Sleep Quality Index (PSQI). Score ranging from 0 to 21, higher score denoting greater acute sleep disturbances. |
At Week 2, Week 11 and Week 18
|
|
Severity of arousal disorders score
Délai: At Week 2, Week 11 and Week 18
|
Using a standardized questionnaire: Paris Arousal Disorders Severity Scale (PADSS). Score ranging from 0 to 50, higher score denoting more severed disorders. |
At Week 2, Week 11 and Week 18
|
|
Circadian typology score
Délai: At Week 2, Week 11 and Week 18
|
Using a standardized questionnaire: Horne & Östberg questionnaire. Score ranging from 16 to 86, higher score denoting morningness and lower score eveningness. |
At Week 2, Week 11 and Week 18
|
|
Changes in sleep architecture
Délai: At Day 0 and Week 11
|
Using power spectral sleep EEG analysis including delta (1-4 Hz), theta (4-8 Hz), alpha (8-12 Hz), sigma (12-16 Hz), and beta (18-30 Hz) frequency bands with Titanium, Embla®, NOX-A1®. |
At Day 0 and Week 11
|
|
Sleep eye movements
Délai: At Week 11 (optional)
|
Using power spectral sleep EOG analysis (left and right) with Titanium, Embla®, NOX-A1®. |
At Week 11 (optional)
|
|
Sleep muscles activity
Délai: At Week 11 (optional)
|
Using power spectral sleep EMG analysis (chin and anterior tibialis muscle) with Titanium, Embla®, NOX-A1® |
At Week 11 (optional)
|
|
Sleep cardiac activity
Délai: At Week 11 (optional)
|
Using power spectral sleep ECG analysis (P wave, QRS complex, QT interval, PR interval...) with Titanium, Embla®, NOX-A1®. |
At Week 11 (optional)
|
|
Sleep oxygen saturation
Délai: At Week 11 (optional)
|
Using sleep oxygen saturation measures with Titanium, Embla®, NOX-A1®. |
At Week 11 (optional)
|
|
Sleep airflow
Délai: At Week 11 (optional)
|
Using sleep airflow measures with Titanium, Embla®, NOX-A1®. |
At Week 11 (optional)
|
|
Sleep respiratory efforts
Délai: At Week 11 (optional)
|
Using abdominal and thoracic respiratory efforts measures with Titanium, Embla®, NOX-A1®. |
At Week 11 (optional)
|
|
Snoring
Délai: At Week 11 (optional)
|
Using snoring measures with Titanium, Embla®, NOX-A1®. |
At Week 11 (optional)
|
|
Changes in imagery processes
Délai: At Day 0 and Week 11 for patients.
|
Using patients' EEG measures (N=60) collected with a 124-channel waveguardTMoriginal EEG cap and during 3-minute pleasant imagery suggestion audio recordings. |
At Day 0 and Week 11 for patients.
|
|
Validation of the EEG methodology for the imagery processes recordings
Délai: At Day 0
|
Using healthy volunteers' EEG measures (N=50) collected with a 124-channel waveguardTMoriginal EEG and during 5-minute pleasant imagery suggestion audio recordings. |
At Day 0
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Chantal Berna Renella, Prof, CHUV
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- CER-VD 2023-01007
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .